All patients
Age < 65y (younger) Age > 75y (older) cell type, non squamous cell cell type, squamous cell ECOG 0 ECOG 1 Gender, female Gender, male metastasis (bone) metastasis (brain) NO metastasis (brain) YES metastasis (liver ) smoker (current or former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
mNSCLC - L1 - PDL1 positive, nivolumab plus ipilimumab vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 227 (NI vs C ; PDL1>1%), 2018 0.79 [0.65; 0.96]
0.79 [0.65 ; 0.96 ] CheckMate 227 (NI vs C ; PDL1>1%), 2018 1 0% 793 NA not evaluable progression or deaths (PFS)detailed results CheckMate 227 (NI vs C ; PDL1>1%), 2018 0.82 [0.69; 0.97]
0.82 [0.69 ; 0.97 ] CheckMate 227 (NI vs C ; PDL1>1%), 2018 1 0% 793 NA not evaluable objective responses (ORR)detailed results CheckMate 227 (NI vs C ; PDL1>1%), 2018 1.31 [0.97; 1.76]
1.31 [0.97 ; 1.76 ] CheckMate 227 (NI vs C ; PDL1>1%), 2018 1 0% 793 NA not evaluable STRAE (any grade)detailed results CheckMate 227 (NI vs C ; PDL1>1%), 2018 1.96 [1.36; 2.83]
1.96 [1.36 ; 2.83 ] CheckMate 227 (NI vs C ; PDL1>1%), 2018 1 0% 778 NA not evaluable STRAE (grade 3-4)detailed results CheckMate 227 (NI vs C ; PDL1>1%), 2018 1.98 [1.32; 2.98]
1.98 [1.32 ; 2.98 ] CheckMate 227 (NI vs C ; PDL1>1%), 2018 1 0% 778 NA not evaluable TRAE (any grade)detailed results CheckMate 227 (NI vs C ; PDL1>1%), 2018 0.66 [0.46; 0.94]
0.66 [0.46 ; 0.94 ] CheckMate 227 (NI vs C ; PDL1>1%), 2018 1 0% 778 NA not evaluable TRAE (grade 3-4)detailed results CheckMate 227 (NI vs C ; PDL1>1%), 2018 0.96 [0.72; 1.29]
0.96 [0.72 ; 1.29 ] CheckMate 227 (NI vs C ; PDL1>1%), 2018 1 0% 778 NA not evaluable TRAE leading to death (grade 5)detailed results CheckMate 227 (NI vs C ; PDL1>1%), 2018 0.99 [0.28; 3.45]
0.99 [0.28 ; 3.45 ] CheckMate 227 (NI vs C ; PDL1>1%), 2018 1 0% 778 NA not evaluable TRAE leading to discontinuation (any grade)detailed results CheckMate 227 (NI vs C ; PDL1>1%), 2018 3.13 [1.95; 5.03]
3.13 [1.95 ; 5.03 ] CheckMate 227 (NI vs C ; PDL1>1%), 2018 1 0% 778 NA not evaluable TRAE leading to discontinuation (grade 3-4)detailed results CheckMate 227 (NI vs C ; PDL1>1%), 2018 5.13 [2.63; 10.00]
5.13 [2.63 ; 10.00 ] CheckMate 227 (NI vs C ; PDL1>1%), 2018 1 0% 778 NA not evaluable Anaemia TRAE (grade 3-4)detailed results CheckMate 227 (NI vs C ; PDL1>1%), 2018 0.11 [0.04; 0.28]
0.11 [0.04 ; 0.28 ] CheckMate 227 (NI vs C ; PDL1>1%), 2018 1 0% 778 NA not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 227 (NI vs C ; PDL1>1%), 2018 1.24 [0.33; 4.65]
1.24 [0.33 ; 4.65 ] CheckMate 227 (NI vs C ; PDL1>1%), 2018 1 0% 778 NA not evaluable Constipation TRAE (grade 3-4)detailed results CheckMate 227 (NI vs C ; PDL1>1%), 2018 0.99 [0.02; 50.01]
0.99 [0.02 ; 50.01 ] CheckMate 227 (NI vs C ; PDL1>1%), 2018 1 0% 778 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results CheckMate 227 (NI vs C ; PDL1>1%), 2018 0.99 [0.25; 3.99]
0.99 [0.25 ; 3.99 ] CheckMate 227 (NI vs C ; PDL1>1%), 2018 1 0% 778 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results CheckMate 227 (NI vs C ; PDL1>1%), 2018 3.00 [0.60; 14.96]
3.00 [0.60 ; 14.96 ] CheckMate 227 (NI vs C ; PDL1>1%), 2018 1 0% 778 NA not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 227 (NI vs C ; PDL1>1%), 2018 2.00 [0.60; 6.70]
2.00 [0.60 ; 6.70 ] CheckMate 227 (NI vs C ; PDL1>1%), 2018 1 0% 778 NA not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 227 (NI vs C ; PDL1>1%), 2018 0.28 [0.06; 1.35]
0.28 [0.06 ; 1.35 ] CheckMate 227 (NI vs C ; PDL1>1%), 2018 1 0% 778 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results CheckMate 227 (NI vs C ; PDL1>1%), 2018 0.01 [0.00; 0.23]
0.01 [0.00 ; 0.23 ] CheckMate 227 (NI vs C ; PDL1>1%), 2018 1 0% 778 NA not evaluable Pruritus TRAE (grade 3-4)detailed results CheckMate 227 (NI vs C ; PDL1>1%), 2018 3.97 [0.18; 88.42]
3.97 [0.18 ; 88.42 ] CheckMate 227 (NI vs C ; PDL1>1%), 2018 1 0% 778 NA not evaluable Rash TRAE (grade 3-4)detailed results CheckMate 227 (NI vs C ; PDL1>1%), 2018 18.21 [1.05; 315.26]
18.21 [1.05 ; 315.26 ] CheckMate 227 (NI vs C ; PDL1>1%), 2018 1 0% 778 NA not evaluable Vomiting TRAE (grade 3-4)detailed results CheckMate 227 (NI vs C ; PDL1>1%), 2018 0.10 [0.01; 0.76]
0.10 [0.01 ; 0.76 ] CheckMate 227 (NI vs C ; PDL1>1%), 2018 1 0% 778 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-14 03:55 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 171
- treatments: 416,864
